The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review

The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review

Over 50% of individuals with esophageal cancer (EC) present with advanced stages of the disease; therefore, their outcome following surgery alone is poor, with only 25%–36% being alive 5 years post-surgery. Based on the evidence that the CROSS and NEOCRTEC5010 trials provided, neoadjuvant chemoradio...

Full description

Bibliographic Details
Main Authors: Dan Han, Baosheng Li, Qian Zhao, Hongfu Sun, Jinling Dong, Shaoyu Hao, Wei Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
esophageal cancer
neoadjuvant chemoradiotherapy
neoadjuvant immunotherapy
pathological complete remission (pCR)
target volume delineation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.890688/full

Similar Items

Similar Items